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Background: Signaling pathways outside dopamine D2 receptor antagonism may govern the variable clinical
profile of antipsychotic drugs (APD) in schizophrenia. One postulated mechanism causal to APD action may
regulate synaptic plasticity and neuronal connectivity via the extracellular signal-regulated kinase (ERK) cascade that
links G-protein coupled receptors (GPCR) and ErbB growth factor signaling, systems disturbed in schizophrenia. This
was based upon our finding that the low D2 receptor affinity APD clozapine induced initial down-regulation and
delayed epidermal growth factor receptor (EGFR or ErbB1) mediated activation of the cortical and striatal ERK
response in vivo distinct from olanzapine or haloperidol. Here we map whether the second generation atypical
APDs aripiprazole and quetiapine affect the EGFR-ERK pathway and its substrates p90RSK and c-Fos in mouse brain,
given their divergent agonist and antagonist properties on dopaminergic transmission, respectively.
Results: In prefrontal cortex, aripiprazole triggered triphasic ERK phosphorylation that was EGFR-independent but
had no significant effect in striatum. Conversely quetiapine did not alter cortical ERK signaling but elevated striatal
ERK levels in an EGFR-dependent manner. Induction of ERK by aripiprazole did not affect p90RSK signaling but
quetiapine decreased RSK phosphorylation within 1-hour of administration. The transcription factor c-Fos by
comparison was a direct target of ERK phosphorylation induced by aripiprazole in cortex and quetiapine in striatum
with protein levels in temporal alignment with that of ERK.
Conclusions: These data indicate that aripiprazole and quetiapine signal to specific nuclear targets of ERK, which
for quetiapine occurs via an EGFR-linked mechanism, possibly indicating involvement of this system in its action.
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Dysfunction of dopamine neurotransmission is considered
a central feature of schizophrenia, with antipsychotic
drugs (APDs) targeting dopamine D2 (D2) receptors to al-
leviate positive psychotic symptoms in about one half of
patients. However the therapeutic window of D2 receptor
blockade (65-78%) within which most APDs achieve
optimal clinical utility does not extend to the atypical
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unless otherwise stated.resistant schizophrenia. Sub-threshold levels of D2 recep-
tor blockade exerted by clozapine argues for a mechanism
of action not solely reliant on D2 receptor antagonism. In
accord with this, we have reported that clozapine signals
to the mitogen-activated protein kinase-extracellular sig-
nal regulated kinase (MAPK-ERK) cascade via G-protein
coupled receptor (GPCR) transactivation of the epidermal
growth factor (EGF) receptor (EGFR or ErbB1) [1-3]. This
was typified by clozapine induced early inhibition and de-
layed activation of the ERK response in prefrontal cortex
(PFC) and striatum dependent on EGFR signaling in vitro
[1] and in vivo [2,3] unlike olanzapine or haloperidol. The
convergence of the ERK cascade with GPCR and growth
factor signaling systems upon activation by APDs is
noteworthy since signal transduction from the cell sur-
face to the nucleus can regulate cortical neurogenesis,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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affected in schizophrenia [4-6]. Whether these cell sig-
naling effects observed with clozapine extend to the
second generation atypical APDs aripiprazole and que-
tiapine has not been tested. This is relevant given that
aripiprazole and quetiapine display agonist and antag-
onist properties in animal models of dopaminergic
hypoactivity and hyperactivity, respectively, share cloza-
pine’s low D2 receptor binding profile (quetiapine) and
are predicted to stabilize dopaminergic transmission.
Aripiprazole differs from other atypical APDs in that it
acts by partial agonism at D2 and serotonin (5HT) 1A
receptors [7]. The drug modulates dopaminergic activity
in areas where dopamine may be increased (mesolimbic
regions) or diminished (mesocortical regions) in the
brains of people with schizophrenia. Like other atypical
APDs, aripiprazole antagonizes 5HT2A receptors and
has moderate affinity for histamine and α-adrenergic re-
ceptors. Quetiapine is a multiple receptor antagonist
with low affinity for D2 and higher affinity for 5HT2A,
5HT1A, α-1 and α-2 adrenergic and histamine H1 re-
ceptors [8]. Positron emission topography studies indi-
cate that quetiapine rapidly disassociates from the D2
receptor producing normal physiological surges of dopa-
mine in the nigrostriatal and tuberoinfundibular tracts
of the brain, thus minimizing the risk of extrapyramidal
side effects (EPS) and elevations in prolactin. For both
aripiprazole and quetiapine, however, effects on down-
stream ERK signaling that can regulate transcription fac-
tors such as Elk1 or CREB to shape gene expression,
protein synthesis and receptor function is less well char-
acterized. In this regard, acute aripiprazole treatment in
mice reduced PFC ERK phosphorylation levels in one re-
corded study to date [9]. By contrast, single time point
experiments in Chinese Hamster Ovary (CHO) cells sta-
bly transfected with D2 short and 5HT1A [10] and D3
receptors [11] indicated that aripiprazole stimulated
ERK phosphorylation via agonist activities at these re-
ceptors. Moreover, Urban et al. [12] reported that ari-
piprazole exerted only partial activation of the ERK
pathway in CHO cells expressing D2 long receptors,
whereas in PC12 cells aripiprazole promoted neurite
outgrowth through activation at 5HT1A rather than D2
receptors and by Ca2+, inositol 1,4,5-triphosphate recep-
tor and ERK signaling [13]. Given the cell-dependent
differences in the intrinsic activity of aripiprazole, a pri-
mary mechanism of action attributable to its functional
selectivity at the D2 receptor and/or combined action
at non-dopamine receptor systems rather than simple
partial agonism has also been argued [12]. Quetiapine
too induces ERK mediated neurite sprouting via Gi/o
coupled receptors in PC12 cells [14], and activated
ERK2 after acute treatment in C6 glioma cells thought
to be related to the putative antidepressant efficacy ofthe drug [15]. In vivo, quetiapine facilitated oligodendro-
cyte development and prevented cuprizone induced cog-
nitive impairments via ERK in mouse cortex [16] and
upregulated ERK gene expression in rat cortex and stri-
atum when administered acutely in conjunction with the
mood stabilizer valproate [17]. Whilst cortical and/or
striatal ERK phosphorylation by aripiprazole and quetia-
pine integrate multiple signaling pathways to regulate
neuronal processes relevant to the symptom domains of
schizophrenia, there remains a paucity of data on the ef-
fects of these APDs on the expression of downstream
proteins such as 90 kDa ribosomal s6 protein kinase
(p90RSK) or c-fos, which potentially define their distinct
clinical profiles.
p90RSK comprising the isoforms RSK1, RSK2 and
RSK3 are a family of broadly expressed serine/threonine
kinases activated by ERK. As a regulator of transcription,
p90RSK phosphorylates the transcription factor cyclic
AMP response element binding (CREB), which leads to
the recruitment of transcriptional co-activators CREB
binding protein and the induction of immediate-early
genes such as c-Fos [18]. ERK1 knock-out mice exhibit
reduced phosphorylation of RSK1 in PFC and striatum,
but not in hippocampus or cerebellum indicating ERK
signaling deficits that are isoform and region-specific [4].
However there is limited data on the effects of APDs on
p90RSK levels, with aripiprazole or quetiapine treatment
effects not documented. Similarly there is limited data
for aripiprazole and quetiapine in relation to c-Fos
which signals a genomic response to a variety of stimuli
including growth factors and neurotransmitters, with
regulation via the phosphorylation of transcription fac-
tors Elk-1 and CREB by ERK and RSK respectively [19].
When compared with other D2 receptor partial agonists,
aripiprazole caused less rotation in nigrostriatal lesioned
rats (hypo-dopaminergic model) but clear Fos induction
in the nucleus accumbens shell, indicative of low intrin-
sic activity despite functional antagonism, a purported
marker of its antipsychotic efficacy [20]. For quetiapine,
elevated c-Fos expression in limbic but not motor re-
lated brain regions [8,21] with a greater increase in Fos
immunoreactivity in rat nucleus accumbens shell than
dorsolateral striatum is in keeping with its atypical index
and reduced EPS propensity [22]. Apart from these data,
the effects of aripiprazole and quetiapine on p90RSK
and c-Fos signaling via the ERK pathway and the interre-
lated EGFR system and how these may differ from cloza-
pine are yet to be profiled.
From this standpoint and to examine whether ERK
pathway signaling and transactivation of the EGFR is a
mechanism that applies to atypical APDs other than clo-
zapine, the studies undertaken here expand our earlier
in vitro neuronal culture and in vivo animal experiments
[1-3] to (i) determine whether acute aripiprazole or
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phorylation over a 24 hr period in mouse PFC or striatum
(ii) assess whether changes in ERK1/2 phosphorylation par-
allel changes in expression of the transcriptional regulators
p90RSK and c-Fos across 24 hrs in PFC or striatum and
(iii) establish if variations in ERK1/2, p90RSK or c-Fos
levels following aripiprazole or quetiapine treatment in cor-
tex or striatum are dependent on EGFR signaling. The PFC
and striatum are examined given their relevance to APD
signaling and innervation by the major dopamine tracts of
the brain, the mesocortical and nigrostriatal pathways, re-
spectively, and also by glutamatergic and gamma-amino-
butyric acid (GABA)-ergic neurons [23]. Both regions are
important in the pathology of schizophrenia, since the PFC
is linked with cognitive, negative and deficit syndrome
symptoms and the striatum with motor control, reward
and decision making and the EPS triggered by some APDs.
Results
A summary of all significant pERK1/2, P-p90RSK and c-Fos
findings in mouse PFC and striatum following aripiprazole
and quetiapine treatment over 24 hrs is provided in Table 1.
Effect of aripiprazole and quetiapine over 24 hours on ERK
phosphorylation in mouse prefrontal cortex and striatum
Exposure to aripiprazole resulted in region-specific
pERK1/2 findings with phosphorylation altered in the PFCTable 1 Summary of the significant pERK1, pERK2, P-p90RSK
striatum following aripiprazole and quetiapine treatment ove























↓ = significantly decreased protein phosphorylation.
↑ = significantly increased protein phosphorylation.
− = no significant change.
APD = antipsychotic drug, min =minutes.(pERK1: F(9, 23) = 5.606, p = 0.0004; pERK2: F(9, 25) = 5.146,
p = 0.0005) (Figure 1A and B) but not in the striatum (data
not shown) Table 1. Triphasic cortical ERK phosphoryl-
ation was noted, with pERK1/2 levels decreased at 20 min
(pERK1: vehicle 100 ± 8% vs aripiprazole 56 ± 5%, p <
0.01), increased by 60 min (pERK1: vehicle 100 ± 13% vs
aripiprazole 158 ± 25%, p < 0.05), decreased by 240 min
(pERK1: vehicle 100 ± 24% vs aripiprazole 49 ± 14%, p <
0.05) and normalised thereafter. The significant effects de-
tected for pERK1 were more apparent than those observed
for pERK2 (Figure 1A and B). By contrast, quetiapine
treatment over a 24 hr period, did not significantly affect
ERK1 and ERK2 phosphorylation in mouse PFC (data not
shown) (Table 1). In striatum, a marked increase in pERK1
activation was observed only at 240 min (F(9, 24) = 6.930,
p < 0.0001; vehicle 100 ± 4% vs quetiapine 144 ± 6%,1
p < 0.01) with levels normalizing by 24 hr (Figure 1A)
while pERK2 levels did not vary significantly between
untreated and quetiapine treated mice at any time point
(Figure 2B).
Effect of aripiprazole and quetiapine in the absence and
presence of AG1478 on ERK phosphorylation in mouse
prefrontal cortex and striatum
For aripiprazole, ERK activation of both isoforms was
observed in the PFC after 60 min of drug treatment
and hence the effect of AG1478 was examined at thisand c-Fos findings in mouse prefrontal cortex and
r 24 hours
60 min 240 min 480 min 24/24
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− − − −
↑ − − −
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Figure 1 Effect of aripiprazole on ERK phosphorylation in C57Bl/6 mouse prefrontal cortex. Representative blots (A) indicate
immunoreactive bands of phosphorylated ERK1 and phosphorylated ERK2 (upper panel) and total ERK1 and total ERK2 (lower panel) levels
following aripiprazole (1 mg/kg) treatment and correspond with the bar graphs below. (B) Aripiprazole treatment over a 24 hr period − pERK1/
ERK1. (C) Aripiprazole treatment over a 24 hr period − pERK2/ERK2. At each time point treated samples were expressed relative to vehicle control
standardized to 100 percent. Data represent the mean ± SEM of at least four mice per experimental group. *p < 0.05; **p < 0.01, statistical
differences between tissue in the absence (vehicle) and presence of aripiprazole are indicated.
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nificant increase in ERK1 and ERK2 phosphorylation
in mouse PFC at 60 min (pERK1: 60 min vehicle 100 ±
8% vs aripiprazole 155 ± 16%, p < 0.01; pERK2: 60 min
vehicle 100 ± 3% vs aripiprazole 144 ± 10%, p < 0.01).
However, these effects were not attenuated by AG1478
(Figure 3A, B and C). Contrary to this, quetiapine
modulation of striatal ERK1 phosphorylation was sig-
nificantly reduced by pre-treatment with AG1478
(pERK1: 240 min quetiapine 228 ± 52% vs quetiapine +
AG1478 70 ± 3%, p < 0.01), whereas AG1478 itself did
not significantly change pERK1 levels relative to ve-
hicle control (Figure 4A and B).Effect of aripiprazole and quetiapine over 24 hours on
p90RSK phosphorylation in mouse prefrontal cortex and
striatum
Aripiprazole significantly altered p90RSK phosphorylation
in the PFC overall compared to vehicle treated animals
(F(9, 23) = 3.485, p < 0.0075) but elevations in p90RSK
phosphorylation at 480 min and 24 hr were not significant
after post hoc corrections (Figure 5A). Similarly, ari-
piprazole administration in mouse striatum produced
non-significant changes in p90RSK phosphorylation with
decreases at 60 and 240 min failing to reach significance
(Figure 5B). Alternatively over a 24 hr period, quetiapine








Figure 2 Effect of quetiapine on ERK phosphorylation in C57Bl/6 mouse striatum. Representative blots (A) indicate immunoreactive bands
of phosphorylated ERK1 and phosphorylated ERK2 (upper panel) and total ERK1 and total ERK2 (lower panel) levels following quetiapine
(5 mg/kg) treatment and correspond with the bar graphs below. (B) Quetiapine treatment over a 24 hr period − pERK1/ERK1. (C) Quetiapine
treatment over a 24 hr period − pERK2/ERK2. At each time point treated samples were expressed relative to vehicle control standardized to
100 percent. Data represent the mean ± SEM of at least four mice per experimental group. **p < 0.01, statistical differences between tissue in the
absence (vehicle) and presence of quetiapine are indicated.
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(F(9, 23) = 3.781, p < 0.0048) (Figure 6A and B). This was at-
tributable to a significant decrease in p90RSK phosphoryl-
ation at 20 min in the PFC (20 min vehicle 100 ± 11% vs
quetiapine 71 ± 5%, p < 0.05) (Figure 6A) whilst in the stri-
atum, significant reductions at 20 and 60 min (20 min ve-
hicle 100 ± 6% vs quetiapine 69 ± 6%, p < 0.05; 60 min
vehicle 100 ± 18% vs quetiapine 56 ± 4%, p < 0.01) were
observed, with levels normalizing thereafter (Figure 6B).
Given that aripiprazole and quetiapine triggered vari-
able patterns of p90RSK phosphorylation in PFC and
striatum but produced no significant increases in eitherregion, the effect of AG1478 exposure to these APDs on
p90RSK phosphorylation was not examined.
Effect of aripiprazole and quetiapine over 24 hours on
c-Fos expression in mouse prefrontal cortex and striatum
Characterization of c-Fos expression in response to aripi-
prazole in the cortex indicated a significant effect of treat-
ment over the 24 hr period (F(9, 25) = 6.616, p < 0.0001)
attributed to an increase at 60 min (vehicle 100 ± 21% vs
aripiprazole 246 ± 26, p < 0.001) (Figure 7A). Fluctuations
in c-Fos levels in the striatum after aripiprazole treatment





















Figure 4 Effect of quetiapine on ERK1 phosphorylation in
C57Bl/6 mouse striatum in the absence or presence of AG1478
(EGF receptor inhibitor) at 240 min. Representative blots
(A) indicate immunoreactive bands of phosphorylated ERK (upper
panel) and total ERK (lower panel) levels at 240 min following
quetiapine (5 mg/kg) ± AG1478 treatment and correspond with the
bar graph below. (B) Effect of AG1478 on quetiapine induced ERK1
phosphorylation at 240 min. Data are expressed relative to vehicle
control standardized to 100 percent and represent the mean ± SEM
of at least four mice per experimental group. *p < 0.05; **p < 0.01,
statistical differences between tissue in the absence (V) and
presence of quetiapine and quetiapine in the absence and presence
of AG1478 are indicated. V = Vehicle, Quet = Quetiapine.
Figure 3 Effect of aripiprazole on ERK phosphorylation in C57Bl/6
mouse prefrontal cortex in the absence or presence of AG1478
(EGF receptor inhibitor). Representative blots (A) indicate
immunoreactive bands of phosphorylated ERK1 and phosphorylated
ERK2 (upper panel) and total ERK1 and total ERK2 (lower panel) levels
following aripiprazole (1 mg/kg) ± AG1478 treatment and correspond
with the bar graphs below. (B) Effect of AG1478 on aripiprazole induced
ERK1 phosphorylation at 60 min. (C) Effect of AG1478 on aripiprazole
induced ERK2 phosphorylation at 60 min. Data are expressed relative to
vehicle control standardized to 100 percent and represent the mean ±
SEM of at least four mice per experimental group. **p< 0.01, statistical
differences between tissue in the absence (V) and presence of
aripiprazole are indicated. V = Vehicle, Ari = Aripiprazole.










Figure 5 Effect of aripiprazole on p90RSK phosphorylation in C57Bl/6 mouse prefrontal cortex and striatum. Representative blots
(A) prefrontal cortex and (C) striatum indicate immunoreactive bands of phospho-p90RSK (upper panel) and RSK1/RSK2/RSK3 (lower panel)
following aripiprazole (1 mg/kg) treatment and correspond with the bar graph below. (B) Aripiprazole treatment over a 24 hr period − prefrontal
cortex. (D) Aripiprazole treatment over a 24 hr period − striatum. At each time point treated samples were expressed relative to vehicle control
standardized to 100 percent. Data represent the mean ± SEM of at least four mice per experimental group.
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zole 226 ± 40, p < 0.05) and 60 min (vehicle 100 ± 27% vs
aripiprazole 285 ± 41, p < 0.01) (Figure 7B). Following que-
tiapine administration, a marked increase in c-Fos protein
was observed at 240 min in PFC (vehicle 100 ± 31% vs
quetiapine 302 ± 24, p < 0.001) and striatum (vehicle 100
± 32% vs quetiapine 444 ± 39, p < 0.001) with levels com-
parable to vehicle treatment at other times across 24 hr
(Figure 8A and B, respectively).
Effect of aripiprazole and quetiapine in the absence and
presence of AG1478 on c-Fos expression in mouse
prefrontal cortex and striatum
The increased c-Fos levels caused by aripiprazole at
60 min in PFC and striatum were not significantly af-
fected by prior administration of AG1478 in eitherregion (PFC: aripiprazole 100 ± 13% vs aripiprazole +
AG1478 140 ± 10%; striatum: aripiprazole 100 ± 1% vs
aripiprazole + AG1478 85 ± 2%, p > 0.05 in both cases).
Similarly for quetiapine, elevations in c-Fos expression
observed at 240 min in cortex and striatum were
not significantly reduced by AG1478 (PFC: quetiapine
100 ± 3% vs quetiapine + AG1478 75 ± 10%; striatum:
quetiapine 100 ± 5% vs quetiapine + AG1478 82 ± 26%,
p > 0.05 in both cases).
Discussion
Aripiprazole and quetiapine differentially regulate ERK
phosphorylation
The mechanisms underlying the action of aripiprazole
and quetiapine on the ERK transduction pathway in PFC









Figure 6 Effect of quetiapine on p90RSK phosphorylation in C57Bl/6 mouse prefrontal cortex and striatum. Representative blots
(A) prefrontal cortex and (C) striatum indicate immunoreactive bands of phospho-p90RSK (upper panel) and RSK1/RSK2/RSK3 (lower panel) following
quetiapine (5 mg/kg) treatment and correspond with the bar graph below. (B) Quetiapine treatment over a 24 hr period − prefrontal cortex.
(D) Quetiapine treatment over a 24 hr period − striatum. At each time point treated samples were expressed relative to vehicle control standardized
to 100 percent. Data represent the mean ± SEM of at least four mice per experimental group. *p < 0.05; **p < 0.01, statistical differences between tissue
in the absence (vehicle) and presence of quetiapine are indicated.
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phosphorylation with pERK1 and pERK2 levels first de-
creased in mouse PFC at 20 min, increased by 60 min,
decreased by 4 hrs and normalised thereafter. No striatal
pERK changes were noted with aripiprazole treatment.
By contrast quetiapine caused no significant changes in
ERK1/2 phosphorylation in cortex, while in striatum
pERK1 activation was only observed at 240 min. More-
over, cortical ERK induction by aripiprazole was inde-
pendent of EGFR activity whereas striatal ERK induction
by quetiapine was EGFR dependent. The observed differ-
ences in pERK1/2 levels were not due to corresponding
variation in total ERK1/2 pools since these remained
relatively stable across experiments. Rather, significantvariability between pERK isoform levels within brain re-
gions at the times tested may suggest that pERK1/2
pools are functionally discrete. Therefore ERK signaling
was affected differently by aripiprazole and quetiapine
in a time-dependent and region-specific manner and
was reliant on EGFR transactivation in the case of
quetiapine.
The ERK profile induced by aripiprazole may be a con-
sequence of the drug’s novel receptor binding properties
that primarily modulate and stabilize the dopamine sys-
tem [7,12]. The efficacy of aripiprazole is proposed to be
mediated through a combination of partial agonist activ-
ity at D2 and 5HT1A receptors and antagonist activity









Figure 7 Effect of aripiprazole on c-Fos expression in C57BL/6 mouse prefrontal cortex and striatum. Representative blots (A) prefrontal
cortex and (C) striatum indicate immunoreactive bands of c-Fos (upper panel) and β-Actin (lower panel) expression following aripiprazole
(1 mg/kg) treatment and correspond with the bar graph below. (B) Aripiprazole treatment over a 24 hr period − prefrontal cortex. (D) Aripiprazole
treatment over a 24 hr period − striatum. At each time point treated samples were expressed relative to vehicle control standardized to 100 percent.
Data represent the mean ± SEM of at least four mice per experimental group. *p < 0.05; **p < 0.01; ***p < 0.001, statistical differences between tissue in
the absence (vehicle) and presence of aripiprazole are indicated.
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served following aripiprazole administration is not
known, they are noteworthy in light of aripiprazole’s
clinical effects. For example, the relatively low risk of
EPS associated with aripiprazole use [25] is presumed to
be due to the drug’s lack of effect on the nigrostriatal
pathway of the brain. The latter is in line with our own
in vivo data indicating an absence of significant changes
in striatal pERK1/2 levels after aripiprazole treatment
over the time course studied. Our cortical finding of
early reduction in ERK1/2 phosphorylation at 20 min
also concurs with a single in vivo study that recorded adecrease in pERK1/2 levels 15 min after acute aripipra-
zole administration, although subsequent time points
were not examined [9]. Drawing valid comparisons be-
tween in vitro experiments utilizing D2, D3 and 5HT1A
receptor-transfected CHO and PC12 cells exposed to
aripiprazole for 5 and 10 min [10-13] and our own
in vivo work is however difficult given the inherent dif-
ferences in the biological systems and time frames
investigated.
The lack of effect of in vivo treatment with quetiapine
in cortex contrasts with the ERK phosphorylation profile









Figure 8 Effect of quetiapine on c-Fos expression in C57BL/6 mouse prefrontal cortex and striatum. Representative blots (A) prefrontal
cortex and (C) striatum indicate immunoreactive bands of c-Fos (upper panel) and β-Actin (lower panel) expression following quetiapine
(5 mg/kg) treatment and correspond with the bar graph below. (B) Quetiapine treatment (5 mg/kg) over a 24 hr period − prefrontal cortex.
(D) Quetiapine treatment (5 mg/kg) over a 24 hr period − striatum. At each time point treated samples were expressed relative to vehicle control
standardized to 100 percent. Data represent the mean ± SEM of at least four mice per experimental group. ***p < 0.001, statistical differences
between tissue in the absence (vehicle) and presence of quetiapine are indicated.
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tagonists. Differences in factors such as proportional
drug receptor occupancy and affinity state may account
for the distinctive ERK signaling response of each APD
[26]. For quetiapine, a dose of 5 mg/kg was chosen to
limit the sedative properties of the drug that are pre-
sumed to occur via histamine H1 receptor antagonist ac-
tivity [16,27]. Therefore sedation is unlikely to be the
reason for the absence of cortical pERK1/2 effects ob-
served. In striatum, quetiapine increased pERK1 activa-
tion only at 240 min, unlike the sustained ERK1
phosphorylation previously seen with haloperidol [2].This is interesting given that quetiapine use is associated
with risk of tardive dyskinesia [28] but to a less extent
than typical APDs [29]. This reduced risk of motor side-
effects is thought to be due to quetiapine’s rapid dissoci-
ation from D2 receptors in the nigrostriatal pathway of
the brain [30]. However inferences on the clinical effects
of quetiapine attributable to ERK activation are limited
since they can only be drawn from a few in vitro cell
studies [14,15], a chronic in vivo mouse study [16] and
an acute rat gene expression study [17]. In this regard,
quetiapine promoted ERK mediated neurite sprouting in
PC12 cells [14] with improvements in affect and mood
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cortex prevented cuprizone induced myelin breakdown
and cognitive impairments via ERK dependent on EGF
[16]. Our data support the latter study insofar as we
show an interaction between quetiapine and the EGFR
in mediating ERK activation in the striatum.
Aripiprazole and quetiapine effects on the downstream
ERK targets p90RSK and c-Fos
Aripiprazole and quetiapine induced p90RSK phosphor-
ylation did not parallel that of ERK unlike for clozapine
[3]. Overall we found that quetiapine decreased p90RSK
levels within 1 hr of administration regardless of its con-
comitant effect on ERK, while aripiprazole did not ap-
preciably affect p90RSK phosphorylation. These data
therefore suggest that in PFC and striatum p90RSK is
unlikely a major downstream target of ERK signaling in
response to aripiprazole or quetiapine and that these
drugs differ from clozapine in the way in which they in-
fluence distal transcriptional measures [3]. In terms of c-
Fos expression however, significant induction at 60 min
by aripiprazole and at 240 min by quetiapine corre-
sponded with increased ERK phosphorylation at the
same time points in PFC and striatum, respectively. The
absence of a time delay between ERK activation and
stimulation of c-Fos by aripiprazole and quetiapine again
contrasts with our clozapine findings in which c-Fos was
expressed subsequent to increases in ERK phosphoryl-
ation [3]. For both drugs, elevations in c-Fos were not
affected by EGFR inhibition. Thus given that quetiapine
induced c-Fos activation in striatum was not affected by
AG1478 but ERK phosphorylation was significantly re-
duced suggests that using a pharmacological agent to
block the EGF receptor, an upstream component of the
pathway, may inadequately affect a downstream nuclear
response. Alternatively, c-Fos activation may have oc-
curred independently of EGFR-ERK pathway induction
via other signaling mechanisms or extracellular mito-
genic stimuli upon in vivo exposure to quetiapine.
For aripiprazole, while c-Fos protein induction in the
PFC has not been previously documented, early 20 min
striatal (ventral and dorsal) up-regulation observed con-
curs with high Fos expression in the nucleus accumbens
shell (ventral striatum) versus lower levels in the dorso-
lateral striatum seen 2 hr after acute administration in
rat and recognized as markers of antipsychotic efficacy
and motor side effects, respectively [20,31]. Similarly for
quetiapine, increased c-Fos expression in PFC and stri-
atum at 240 min is in general accordance with acute
[22] and chronic [21] data in rat, where Fos-like immu-
noreactivity was elevated in PFC and ventral striatum al-
though the temporal link to ERK signaling in striatum
has not been reported before. While it is understood
that APDs do not reach complete effectiveness after asingle dose, the present findings are of mechanistic value
and allow future studies to be designed to examine
whether there is any difference in signaling induced by
sustained treatment with these agents. Moreover, the
current studies utilizing mouse neuronal tissue to exam-
ine the signaling and hence phosphorylation status of
proteins relevant to APD action cannot be undertaken
in human subjects (with schizophrenia). Therefore the
animal experiments described permit some delineation
of the specific intracellular pathways targeted by APDs.
In doing so, these studies may point to potential candidate
proteins and mechanisms affected by APDs and may shed
light on psychotic disorders such as schizophrenia.
Antipsychotic drugs and the EGF receptor system
We had earlier proposed that clozapine may be unique
in recruiting the EGFR system to target ERK and that
this may have some bearing on clozapine’s unequaled
ability to treat drug resistant schizophrenia [1-3]. Here
in keeping with our hypothesis ERK induction by aripi-
prazole was EGFR independent but contrary to our sup-
position, quetiapine induced ERK activation was EGFR
dependent. There are however important differences be-
tween quetiapine and clozapine signaling including: i)
Regional differences in ERK expression. Quetiapine acti-
vated ERK in striatum only and had no effect in the PFC
whereas clozapine was able to induce ERK in mouse
PFC and striatum. ii) Temporal differences in ERK ex-
pression. Quetiapine affected striatal ERK phosphoryl-
ation at 240 min but not at other time points across the
treatment schedule. By contrast, clozapine inhibited ERK
phosphorylation within 1 hr of administration, and then
activated ERK at 480 min in both brain regions. There-
fore, while quetiapine and clozapine share the ability to
recruit the EGFR to signal to ERK, they nevertheless
control ERK phosphorylation differently. Notably, que-
tiapine is not effective in treatment resistant schizophrenia
unlike clozapine. Whether differences in ERK expression
provide additional benefits for clozapine-treated patients
that may account for the drug’s greater efficacy over other
APD remains to be addressed.
The regulation of the EGFR by quetiapine and cloza-
pine is a novel mechanism of APD action with potential
implications for the treatment of schizophrenia. Besides
playing a central role in the development of midbrain
dopaminergic neurons, impaired EGF system function-
ing has been linked to the pathogenesis of the disorder.
For example, genetic association studies have identified
the EGF and NRG1 genes as candidates that confer risk
for schizophrenia [32] with an A61G single nucleotide
polymorphism in the EGF gene associated with early dis-
ease onset in male patients [33]. As well in human post-
mortem brain in schizophrenia, increased EGFR density
was considered to offset the low EGF levels noted [34].
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ing resulted in behavioural brain abnormalities in adult-
hood consistent with those present in animal models of
schizophrenia [35], the EGF family of ligands and recep-
tors also affect neuronal growth, differentiation and survival
later in development [36]. Thus given that several studies
argue for EGF system disturbance in schizophrenia, the
current findings indicate a possible corrective role for APDs
such as quetiapine.
Just which GPCR is employed by quetiapine or cloza-
pine to undertake EGFR transactivation is unclear. Both
APDs share the property of being D2/5HT2A antagonists.
While we have demonstrated in primary mouse cortical
neurons that clozapine induced transactivation of the
EGFR occurred independently of the D2 or 5HT2A recep-
tor [1], whether this holds true for quetiapine is unclear.
The transactivation pathway that signals to the EGFR also
needs to be elucidated for quetiapine and clozapine, bear-
ing in mind that there may be regional differences.
Conclusions
These in vivo studies highlight that the atypical APDs
aripiprazole and quetiapine exert unique temporal and
regional regulation of the convergent EGFR-ERK path-
way and its downstream transcriptional targets, p90RSK
and c-Fos in PFC and striatum that may account for
their distinctive clinical profiles. In this regard, cortical
pERK1 stimulation by aripiprazole was EGFR independ-
ent whereas striatal pERK1 activation by quetiapine was
EGFR dependent. While aripiprazole induction of ERK
had no significant specific effect on p90RSK signaling,
quetiapine reduced RSK phosphorylation early after ex-
posure. By contrast, c-Fos expression induced by aripi-
prazole in cortex and quetiapine in striatum temporally
aligned with ERK phosphorylation and was indicative of
transcriptional regulation as a direct corollary of APD
induced ERK signaling. Collectively, these data provide
further evidence that APD action via ERK may be linked
to the EGF signaling system, perturbations of which have
been documented in schizophrenia and suggest a remed-
ial role for APDs such as quetiapine.
Methods
Drugs and reagents
All reagents were obtained from Sigma-Aldrich, Missouri,
USA unless stipulated otherwise. Quetiapine was donated
by AstraZeneca, Stockholm, Sweden; aripiprazole by
Bristol-Myers Squibb, New Jersey, USA and AG1478
(EGFR inhibitor) purchased from A.G. Scientific, Inc.,
California, USA. Primary antibodies, including phospho-
p44/42 MAPK, p44/42 MAP kinase, phospho-p90RSK,
RSK1/RSK2/RSK3 and β-Actin were from Cell Signaling
Technology, Massachusetts, USA and c-Fos from Assay
Designs, Michigan, USA. Secondary antibodies, includinggoat anti-mouse and goat anti-rabbit horseradish peroxid-
ase (HRP)-conjugated immunoglobulins (IgGs) were sup-
plied by DAKO, NSW, Australia.
Animals
Animal care and experimental procedures were con-
ducted in accordance with The University of Melbourne
Animal Ethics Committee guidelines. Male, 7 week old
C57Bl/6 mice were housed under standard laboratory
conditions on a 12-hour light–dark cycle (lights on
07:00 hr) and provided free access to food and water.
Animals were habituated to the laboratory facility for
one week; were handled daily to reduce acute stress and
were weighed before drug treatment.
Aripiprazole and quetiapine time course studies
For acute time course experiments, groups of mice (n = 4)
were treated via intraperitoneal (IP) injection with the
APDs aripiprazole (1 mg/kg) or quetiapine (5 mg/kg) dis-
solved in 0.9% saline acidified with 0.1 N HCl or vehicle
(1% v/v) as a single dose and were left for 20, 60, 240,
480 min or 24 hr after administration. The doses injec-
ted were in the mid-range of those used in mouse stu-
dies and in line with APD dose in humans. Such doses
were also known to cause effects consistent with anti-
psychotic mouse models of psychosis without sedation
[1,27,37,38]. Directly following the time interval speci-
fied and in order to preserve phospho-proteins, mice
were decapitated, the head immersed in liquid nitro-
gen for 6 sec, the brain rapidly removed and PFC and
striatum dissected out within 20 sec on an ice-cold plat-
form [2,3]. Brain tissue was sonicated in 1% SDS (750 μl),
boiled for 10 min and frozen at −80°C until assayed.
Before protein determination, lysates were centrifuged
at 14000 × g for 5 min at 4°C to remove insoluble mater-
ial. Lysate protein content was measured by the Bradford
method (Bio-Rad Protein Assay, California, USA) using
BSA as standard. Brain lysates were assayed for phospho-
rylated and total ERK1, ERK2, p90RSK and c-Fos levels as
outlined.
AG1478 treatment studies
To determine the effect of EGFR inhibition on ERK
phosphorylation and c-Fos expression, mice (n = 4 per
group) were treated with AG1478 (EGFR inhibitor) at
25 mg/kg dissolved in 50% DMSO 10 min prior to APD
or vehicle administration. In the case of aripiprazole and
quetiapine, co-treatment with AG1478 was performed
at 60 and 240 min, respectively, time points at which
each drug had significantly activated ERK and c-Fos
above vehicle. For experiments that spanned 240 min,
two injections of AG1478 were given 2 hr apart to main-
tain adequate plasma levels [39]. At the experimental
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ERK1/2, p90RSK and c-Fos assay
Aliquots of 15–30 μg of PFC and striatal protein lysate
were separated by SDS-PAGE and immunoblotted using
standard methods. Proteins were electrotransferred to
nitrocellulose membrane (Osmonics, Minnesota, USA)
and blocked at room temperature for 90 min in 5% skim
milk powder, TBST (20 mM Tris-Base pH 7.5, 150 mM
NaCl, 0.01% Tween-20). Membranes were incubated
overnight with primary phospho-p44/42 MAP Kinase
(Thr202/Tyr204) (E10) antibody (1:2000) in blocking
buffer or phospho-p90RSK (Thr359/Ser363) antibody
(1:1000) in 5% BSA and secondary goat anti-mouse and
goat anti-rabbit HRP-conjugated IgGs (1:2000), respect-
ively, in blocking buffer for 90 min at 4°C. c-Fos levels
were assessed using c-Fos (8B5) mouse monoclonal anti-
body (1:500) and goat anti-mouse HRP-conjugated IgGs
(1:2000) in blocking buffer. Following primary and sec-
ondary antibody exposure, membranes were washed
twice in TBST for 15 min at room temperature. Immu-
noreactive bands were detected using ECL Western
Blotting Detection Reagents, (Amersham Biosciences,
Buckinghamshire, UK) and Hyperfilm ECL (Amersham
Biosciences). To ensure uniform loading, membranes
were stripped in 62.5 mM Tris–HCl at pH 6.7, 2% SDS
and 100 mM β-mercaptoethanol buffer at 50°C for
30 min and re-probed with p44/42 MAP Kinase anti-
body (1:1000) in 5% skim milk, TBST or RSK1/RSK2/
RSK3 (32D7) rabbit monoclonal antibody (1:1000) in 5%
BSA and goat anti-rabbit HRP-conjugated IgGs (1:2000)
for measurement of total ERK1, ERK2 and RSK levels,
respectively. Since c-Fos (8B5) detected endogenous levels
of total c-Fos protein, β-Actin (13E5) rabbit monoclonal
antibody (1:2000) in 5% BSA was used as a loading con-
trol. Proteins were quantified using Multi Gauge Software
(Fujifilm V3.0). The optical densities of phosphorylated
ERK1 (pERK1), phosphorylated ERK2 (pERK2), phosphor-
ylated p90RSK (P-p90RSK) or c-Fos immunoreactive
bands were measured, normalized to the optical densities
of total ERK1 (ERK1), total ERK2 (ERK2), total RSK and
β-Actin, respectively, and expressed as a percentage of ve-
hicle treated control.
Data analysis
Animal data was pooled with each treatment group re-
peated in quadruplicate and the mean ± standard error
of the mean (SEM) calculated using GraphPad Prism 5
software (GraphPad Software Inc., California, USA). Var-
iables were assessed using one-way analysis of variance
(ANOVA) and corrected by post hoc Bonferroni mul-
tiple comparison tests to discriminate differences be-
tween control and treated groups. Unpaired Student’s(2-tailed) t-tests for comparison between pairs of vari-
ables were used as appropriate.
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